Non-Melanoma Skin Cancer in Transplant Recipients: A Single-Centre Retrospective Cohort Study on the Role of Transplant Type, Immunosuppressive Exposure, and Tumor Subtypes.
Non-melanoma skin cancer (NMSC) is a frequent long-term complication in transplant recipients, mainly due to chronic immunosuppression. Its incidence varies by transplant type and regimen, but existing evidence is often fragmented.
To assess long-term incidence and risk factors for NMSC, comparing transplant types, immunosuppressive regimens, and tumor subtypes.
This retrospective cohort comprised 901 transplant recipients (1975-2024) who were under long-term dermatologic follow-up. Data on transplant type, immunosuppressive regimen/duration, and tumor subtype were analyzed. NMSC-free survival was evaluated with Kaplan-Meier curves; Cox regression assessed predictors.
Among 901 transplant recipients, 191 (21.2%) developed at least one NMSC during long-term follow-up. Crude incidence rates ranged between 1.88 and 2.68 per 100 person-years across immunosuppressive drug classes and agents. In multivariable Cox models, older age at first transplant was independently associated with higher NMSC risk (HR 1.07 per year, 95% CI 1.06-1.09, p < 0.001). Sex, transplant group, and ever-use of individual immunosuppressive agents were not significantly associated with NMSC risk after adjustment.
In this long-term cohort, NMSC risk increased with age at first transplant, whereas transplant organ and ever-use of major immunosuppressive agents were not independently associated in adjusted models. Over an extended follow-up, NMSC accumulated steadily, with crude incidence rates around 1.88-2.68 cases per 100 person-years across immunosuppressive classes and agents, underscoring the cumulative nature of skin cancer risk under chronic immunosuppression. Our results reinforce the need for sustained, long-term dermatologic surveillance, particularly in older patients undergoing transplantation.
To assess long-term incidence and risk factors for NMSC, comparing transplant types, immunosuppressive regimens, and tumor subtypes.
This retrospective cohort comprised 901 transplant recipients (1975-2024) who were under long-term dermatologic follow-up. Data on transplant type, immunosuppressive regimen/duration, and tumor subtype were analyzed. NMSC-free survival was evaluated with Kaplan-Meier curves; Cox regression assessed predictors.
Among 901 transplant recipients, 191 (21.2%) developed at least one NMSC during long-term follow-up. Crude incidence rates ranged between 1.88 and 2.68 per 100 person-years across immunosuppressive drug classes and agents. In multivariable Cox models, older age at first transplant was independently associated with higher NMSC risk (HR 1.07 per year, 95% CI 1.06-1.09, p < 0.001). Sex, transplant group, and ever-use of individual immunosuppressive agents were not significantly associated with NMSC risk after adjustment.
In this long-term cohort, NMSC risk increased with age at first transplant, whereas transplant organ and ever-use of major immunosuppressive agents were not independently associated in adjusted models. Over an extended follow-up, NMSC accumulated steadily, with crude incidence rates around 1.88-2.68 cases per 100 person-years across immunosuppressive classes and agents, underscoring the cumulative nature of skin cancer risk under chronic immunosuppression. Our results reinforce the need for sustained, long-term dermatologic surveillance, particularly in older patients undergoing transplantation.
Authors
Zengarini Zengarini, Tagnin Tagnin, Sorbi Sorbi, Guglielmo Guglielmo, La Placa La Placa, Piraccini Piraccini, Pileri Pileri, Pignatti Pignatti
View on Pubmed